{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:39:23Z","timestamp":1787585963222,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2013,12,3]],"date-time":"2013-12-03T00:00:00Z","timestamp":1386028800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1007\/s00280-013-2359-7","type":"journal-article","created":{"date-parts":[[2013,12,2]],"date-time":"2013-12-02T05:52:52Z","timestamp":1385963572000},"page":"373-380","source":"Crossref","is-referenced-by-count":64,"title":["First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancer"],"prefix":"10.1007","volume":"73","author":[{"given":"Muhammad Wasif","family":"Saif","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynne","family":"Lamb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Kaley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Elligers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaoli","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Bussom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shwu-Huey","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yung-Chi","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,12,3]]},"reference":[{"key":"2359_CR1","volume-title":"Cancer facts and figures\u00a02013","author":"American Cancer Society","year":"2013","unstructured":"American Cancer Society (2013) Cancer facts and figures\u00a02013. American Cancer Society, Atlanta"},{"key":"2359_CR2","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","volume":"15","author":"HA Burris 3rd","year":"1997","unstructured":"Burris HA 3rd, Moore MJ, Andersen J et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403\u20132413","journal-title":"J Clin Oncol"},{"issue":"11","key":"2359_CR3","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1016\/j.ejca.2011.04.011","volume":"47","author":"U Pelzer","year":"2011","unstructured":"Pelzer U, Schwaner I, Stieler J, Adler M, Seraphin J, D\u00f6rken B, Riess H, Oettle H (2011) Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer 47(11):1676\u20131681","journal-title":"Eur J Cancer"},{"issue":"34","key":"2359_CR4","doi-asserted-by":"crossref","first-page":"8679","DOI":"10.1200\/JCO.2005.02.0628","volume":"23","author":"MW Saif","year":"2005","unstructured":"Saif MW, Eloubeidi MA, Russo S, Steg A, Thornton J, Fiveash J, Carpenter M, Blanquicett C, Diasio RB, Johnson MR (2005) Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome. J Clin Oncol 23(34):8679\u20138687","journal-title":"J Clin Oncol"},{"issue":"1","key":"2359_CR5","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1200\/JCO.20.1.160","volume":"20","author":"TH Cartwright","year":"2002","unstructured":"Cartwright TH, Cohn A, Varkey JA, Chen YM, Szatrowski TP, Cox JV, Schulz JJ (2002) Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol 20(1):160\u2013164","journal-title":"J Clin Oncol"},{"issue":"3\u20134","key":"2359_CR6","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000127413","volume":"73","author":"S Boeck","year":"2007","unstructured":"Boeck S, Wilkowski R, Bruns CJ, Issels RD, Schulz C, Moosmann N, Laessig D, Haas M, Golf A, Heinemann V (2007) Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer. Oncology 73(3\u20134):221\u2013227","journal-title":"Oncology"},{"issue":"33","key":"2359_CR7","doi-asserted-by":"crossref","first-page":"5513","DOI":"10.1200\/JCO.2009.24.2446","volume":"27","author":"D Cunningham","year":"2009","unstructured":"Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W, Harper PG, Dunn J, Tudur-Smith C, West J, Falk S, Crellin A, Adab F, Thompson J, Leonard P, Ostrowski J, Eatock M, Scheithauer W, Herrmann R, Neoptolemos JP (2009) Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 27(33):5513\u20135518","journal-title":"J Clin Oncol"},{"issue":"7","key":"2359_CR8","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1200\/JCO.2003.09.016","volume":"21","author":"W Scheithauer","year":"2003","unstructured":"Scheithauer W, Kornek GV, Raderer M, Schull B, Schmid K, Kovats E, Schneeweiss B, Lang F, Lenauer A, Depisch D (2003) Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 21(7):1307\u20131312","journal-title":"J Clin Oncol"},{"issue":"6","key":"2359_CR9","doi-asserted-by":"crossref","first-page":"703","DOI":"10.6004\/jnccn.2012.0073","volume":"10","author":"MA Tempero","year":"2012","unstructured":"Tempero MA, Arnoletti JP, Behrman SW, Ben-Josef E, Benson AB III, Casper ES, Cohen SJ, Czito B, Ellenhorn JD, Hawkins WG, Herman J, Hoffman JP, Ko A, Komanduri S, Koong A, Ma WW, Malafa MP, Merchant NB, Mulvihill SJ, Muscarella P II, Nakakura EK, Obando J, Pitman MB, Sasson AR, Tally A, Thayer SP, Whiting S, Wolff RA, Wolpin BM, Freedman-Cass DA, Shead DA (2012) National comprehensive cancer networks. Pancreatic adenocarcinoma, version 2.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 10(6):703\u2013713","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"2359_CR10","first-page":"30","volume":"20","author":"R Rilton","year":"2010","unstructured":"Rilton R, Paiva AA, Guan J, Marathe R, Jiang Z, van Eyndhoven W, Bjoraker J, Wang H, Liu SH, Cheng Y-C (2010) PhytomicsQC: a comprehensive approach to define quality control of botanical drugs\u2014a case study of PHY906. Chin Med 20(5):30","journal-title":"Chin Med"},{"issue":"37","key":"2359_CR11","doi-asserted-by":"crossref","first-page":"5785","DOI":"10.1016\/j.chroma.2010.07.045","volume":"1217","author":"W Zhang","year":"2010","unstructured":"Zhang W, Saif MW, Dutschman GE, Li X, Lam W, Bussom S, Jiang Z, Ye M, Chu E, Cheng YC (2010) Identification of chemicals and their metabolites from PHY906, a Chinese medicine formulation, in the plasma of a patient treated with irinotecan and PHY906 using liquid chromatography\/tandem mass spectrometry (LC\/MS\/MS). J Chromatogr A 1217(37):5785\u20135793","journal-title":"J Chromatogr A"},{"issue":"2","key":"2359_CR12","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.clcc.2011.03.003","volume":"10","author":"S Kummar","year":"2011","unstructured":"Kummar S, Copur MS, Rose M, Wadler S, Stephenson J, O\u2019Rourke M, Brenckman W, Tilton R, Liu SH, Jiang Z, Su T, Cheng YC, Chu E (2011) A phase I study of the Chinese herbal medicine PHY906 as a modulator of irinotecan-based chemotherapy in patients with advanced colorectal cancer. Clin Colorectal Cancer 10(2):85\u201396","journal-title":"Clin Colorectal Cancer"},{"issue":"10","key":"2359_CR13","first-page":"4083","volume":"29","author":"Y Yen","year":"2009","unstructured":"Yen Y, So S, Rose M, Saif MW, Chu E, Liu SH, Foo A, Jiang Z, Su T, Cheng YC (2009) Phase I\/II study of PHY906\/capecitabine in advanced hepatocellular carcinoma. Anticancer Res 29(10):4083\u20134092","journal-title":"Anticancer Res"},{"key":"2359_CR14","unstructured":"Liu S-H, Jiang Z, Gao W et al (2003) PHY906, a Chinese herbal formulation enhances the therapeutic effect of cancer chemotherapy in human colorectal and liver cancer. Proc Am Soc Clin Oncol. Abstr #864"},{"key":"2359_CR15","doi-asserted-by":"crossref","unstructured":"Saif MW, Liu S, Elfiky A, Jiang Z, Cheng Y (2007) Synergistic activity of PHY906 with capecitabine in pancreatic carcinoma. J Clin Oncol; ASCO annual meeting proceedings part I. Vol 25, No. 18S (June 20 Supplement), 2007:15116","DOI":"10.1200\/jco.2007.25.18_suppl.15116"},{"issue":"3\u20134","key":"2359_CR16","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.phymed.2009.12.016","volume":"17","author":"MW Saif","year":"2010","unstructured":"Saif MW, Lansigan F, Ruta S, Lamb L, Mezes M, Elligers K, Grant N, Jiang ZL, Liu SH, Cheng YC (2010) Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and other gastrointestinal malignancies. Phytomedicine 17(3\u20134):161\u2013169","journal-title":"Phytomedicine"},{"key":"2359_CR17","unstructured":"http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3.pdf"},{"key":"2359_CR18","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205\u2013216","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"2359_CR19","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s00520-005-0834-3","volume":"14","author":"C Moro","year":"2006","unstructured":"Moro C, Brunelli C, Miccinesi G, Fallai M, Morino P, Piazza M, Labianca R, Ripamonti C, Moro C, Brunelli C, Miccinesi G, Fallai M, Morino P, Piazza M, Labianca R, Ripamonti C (2006) Edmonton symptom assessment scale: Italian validation in two palliative care settings. Support Care Cancer 14(1):30\u201337","journal-title":"Support Care Cancer"},{"issue":"3","key":"2359_CR20","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.clim.2003.11.017","volume":"110","author":"E Morgan","year":"2004","unstructured":"Morgan E, Varro R, Sepulveda H, Ember JA, Apgar J, Wilson J, Lowe L, Chen R, Shivraj L, Agadir A, Campos R, Ernst D, Gaur A (2004) Cytometric bead array: a multiplexed assay platform with applications in various areas of biology. Clin Immunol 110(3):252\u2013266","journal-title":"Clin Immunol"},{"issue":"2","key":"2359_CR21","first-page":"83","volume":"9","author":"SP Kang","year":"2008","unstructured":"Kang SP, Saif MW (2008) Optimal second line treatment options for gemcitabine refractory advanced pancreatic cancer patients. Can we establish standard of care with available data? JOP 9(2):83\u201390","journal-title":"JOP"},{"key":"2359_CR22","unstructured":"Liu S-H, Jiang Z, Leung D, Lee Y, Cheng Y (2004) PHY906: enhancement of cancer chemotherapeutic agents and insights into mechanism of action. Proceedings of medicine in the 21st century tri-conference and bio-forum, vol 77"},{"issue":"11","key":"2359_CR23","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1200\/JCO.2007.13.8388","volume":"26","author":"TA Traina","year":"2008","unstructured":"Traina TA, Theodoulou M, Feigin K et al (2008) Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer. J Clin Oncol 26(11):1797\u20131802","journal-title":"J Clin Oncol"},{"key":"2359_CR24","first-page":"588","volume":"61","author":"J Le","year":"1989","unstructured":"Le J, Vilcek I (1989) Interleukin-6: a multifunctional cytokine regulating immune reactions and the acute phase protein response. Lab Invest 61:588\u2013602","journal-title":"Lab Invest"},{"issue":"4","key":"2359_CR25","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/0002-9378(91)90582-C","volume":"164","author":"JS Berek","year":"1991","unstructured":"Berek JS, Chung C, Kaldi K, Watson JM, Knox RM, Mart\u00ednez-Maza O (1991) Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer. Am J Obstet Gynecol 164(4):1038\u20131042 discussion 1042\u20133","journal-title":"Am J Obstet Gynecol"},{"issue":"6","key":"2359_CR26","first-page":"583","volume":"5","author":"O Mart\u00ednez-Maza","year":"1991","unstructured":"Mart\u00ednez-Maza O, Berek JS (1991) Interleukin 6 and cancer treatment. In Vivo 5(6):583\u2013588","journal-title":"In Vivo"},{"issue":"5","key":"2359_CR27","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1172\/JCI115767","volume":"89","author":"G Strassmann","year":"1992","unstructured":"Strassmann G, Fong M, Kenney JS, Jacob CO (1992) Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J Clin Invest 89(5):1681","journal-title":"J Clin Invest"},{"issue":"8\u20139","key":"2359_CR28","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1051\/medsci\/20082489694","volume":"24","author":"A Gougelet","year":"2008","unstructured":"Gougelet A, Mansuy A, Blay JY (2008) Interleukin-6 and epithelial tumours: new convincing arguments in favour of the use of IL-6 targeted therapies. Med Sci (Paris) 24(8\u20139):694\u2013696","journal-title":"Med Sci (Paris)"},{"issue":"4","key":"2359_CR29","first-page":"340","volume":"14","author":"J Jarboe","year":"2013","unstructured":"Jarboe J, Saif MW (2013) First line therapy for metastatic pancreatic cancer. JOP 14(4):340\u2013343","journal-title":"JOP"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-013-2359-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-013-2359-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-013-2359-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T04:30:46Z","timestamp":1597120246000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-013-2359-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,3]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["2359"],"URL":"https:\/\/doi.org\/10.1007\/s00280-013-2359-7","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,3]]}}}